Moderna (MRNA) Stock Forecast & Price Target

Q: What analysts cover Moderna?

Moderna has been rated by research analysts at Argus , Bank of America , Barclays , Bradesco Corretora , Brookline Capital Markets , Citigroup , CLSA , Deutsche Bank Aktiengesellschaft , Jefferies Financial Group , JPMorgan Chase & Co. , Loop Capital , Morgan Stanley , Piper Sandler , Rothschild & Co Redburn , Royal Bank Of Canada , The Goldman Sachs Group , UBS Group , Weiss Ratings , William Blair , and Wolfe Research in the past 90 days.

$154.03 -4.04 (-2.56%)

Closing price 09/18/2026 03:59 PM Eastern

Extended Trading

$153.90 -0.13 (-0.09%)

As of 09/18/2026 07:59 PM Eastern

Compare

Moderna - Analysts' Recommendations and Stock Price Forecast (2026)

Consensus Rating

Hold

Based on 24 Analyst Ratings

Sell
5

Hold
12

Buy
7

Based on 24 Wall Street analysts who have issued ratings for Moderna in the last 12 months, the stock has a consensus rating of "Hold." Out of the 24 analysts, 5 have given a sell rating, 12 have given a hold rating, and 7 have given a buy rating for MRNA.

Consensus Price Target

$76.72
-50.19% Downside

According to the 24 analysts' twelve-month price targets for Moderna, the average price target is $76.72. The highest price target for MRNA is $180.00, while the lowest price target for MRNA is $18.00. The average price target represents a forecasted downside of -50.19% from the current price of $154.03.

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Get the Latest News and Ratings for MRNA and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Moderna and its competitors.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

MRNA Analyst Ratings Over Time

Type	Current Forecast 9/20/25 to 9/20/26	1 Month Ago 8/21/25 to 8/21/26	3 Months Ago 6/22/25 to 6/22/26	1 Year Ago 9/20/24 to 9/20/25
Strong Buy	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	7 Buy rating(s)	4 Buy rating(s)	2 Buy rating(s)	3 Buy rating(s)
Hold	12 Hold rating(s)	11 Hold rating(s)	11 Hold rating(s)	14 Hold rating(s)
Sell	5 Sell rating(s)	4 Sell rating(s)	5 Sell rating(s)	4 Sell rating(s)
Consensus Price Target	$76.72	$69.50	$36.60	$41.81
Forecasted Upside	-50.19% Downside	-52.09% Downside	-38.33% Downside	65.66% Upside
Consensus Rating	Hold	Hold	Reduce	Reduce

MRNA Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

MRNA Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Moderna Stock vs. The Competition

Type	Moderna	Healthcare Companies	Broader Market
Consensus Rating Score	2.08	2.30	2.53
Consensus Rating	Hold	Hold	Moderate Buy
Predicted Upside	-50.19% Downside	754.93% Upside	18.44% Upside
News Sentiment Rating	Neutral News See Recent MRNA News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export

Date	Brokerage	Analyst	Action	Rating	Price Target	Report Date Upside/Downside
9/9/2026	Weiss Ratings 5 of 5 stars		Reiterated Rating	Sell (D-)
9/3/2026	UBS Group 4 of 5 stars	Michael Yee Not Rated	Set Target		$81.00	-46.29%
9/3/2026	Rothschild & Co Redburn 4 of 5 stars	Simon Baker Not Rated	Downgrade	Neutral ➝ Sell	$40.00 ➝ $81.00	-46.29%
8/28/2026	CLSA Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Upgrade	Outperform
8/28/2026	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Initiated Coverage	Hold
8/28/2026	William Blair Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Myles Minter Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Initiated Coverage	Outperform
8/28/2026	Bradesco Corretora Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Upgrade	Outperform
8/28/2026	Argus Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	John Eade Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Upgrade	Hold ➝ Buy	$180.00	+26.08%
8/25/2026	Wolfe Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Alexandria Hammond Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Upgrade	Underperform ➝ Peer Perform
8/24/2026	Barclays Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Eliana Merle Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Equal Weight	$48.00 ➝ $125.00	-13.83%
Get the Latest News and Ratings for MRNA and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for Moderna and its competitors with MarketBeat's FREE daily newsletter.
8/21/2026	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Jessica Fye Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Underweight	$40.00 ➝ $77.00	-47.67%
8/20/2026	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Terence Flynn Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Equal Weight	$39.00 ➝ $89.00	-48.96%
8/19/2026	The Goldman Sachs Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Salveen Richter Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Neutral	$67.00 ➝ $120.00	-31.49%
8/19/2026	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Luca Issi Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	Sector Perform	$130.00	-9.85%
8/19/2026	Loop Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Leah Rush Cann Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Set Target		$135.00	-6.39%
8/19/2026	Brookline Capital Markets Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Reiterated Rating	Buy
8/19/2026	Jefferies Financial Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Reiterated Rating	Hold
8/19/2026	Bank of America Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Dimple Gosai Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Upgrade	Underperform ➝ Neutral
8/3/2026	Piper Sandler Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Edward Tenthoff Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	Overweight
8/3/2026	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Geoff Meacham Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Neutral	$41.00 ➝ $60.00	+9.45%
2/17/2026	Evercore Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Cory Kasimov Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Set Target		$35.00	-18.79%
2/17/2026	Sanford C. Bernstein Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Reiterated Rating	Market Perform	$45.00	+6.56%
1/30/2026	Leerink Partners Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Mani Foroohar Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	Underperform
1/29/2026	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Reiterated Rating	Hold
1/12/2026	BMO Capital Markets Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Upgrade	Market Perform ➝ Buy
11/17/2025	Berenberg Bank Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Set Target		$28.00	+13.04%
10/20/2025	Needham & Company LLC Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Joseph Stringer Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	Hold
7/13/2025	Wells Fargo & Company Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Reiterated Rating	Equal Weight
11/18/2024	HSBC Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Upgrade	Hold ➝ Buy	$58.00	+57.39%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Sunday at 04:56 PM ET.

Should I Buy Moderna Stock? MRNA Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Tuesday, September 15, 2026. Please send any questions or comments about these Moderna pros and cons to contact@marketbeat.com.

Moderna
Bull Case

Here are some ways that investors could benefit from investing in Moderna, Inc.:

Moderna, Inc. recently reported that its AI-driven personalized cancer vaccine program, developed in partnership with Merck, successfully cleared a Phase 3 clinical trial, marking a significant milestone that could provide a major growth opportunity beyond the company's declining COVID-19 vaccine demand.
The stock is currently trading at $143.77, which represents a substantial recovery from its fifty-two-week low of $22.28, indicating strong market momentum and investor confidence in the company's post-pandemic strategic pivot toward oncology and other therapeutic areas.
Investors are increasingly viewing Moderna, Inc.'s broader mRNA pipeline, including commercial products for respiratory syncytial virus and programs targeting influenza and rare diseases, as potential drivers of a sustainable business turnaround following the pandemic era.
The company recently reported better-than-expected quarterly results with revenue of $145 million, significantly beating the consensus estimate of $102.9 million, which demonstrates an ability to generate stronger top-line growth than analysts had projected.
Updated COVID-19 shots and new mRNA vaccines are rolling out ahead of the upcoming flu season, providing near-term support for Moderna, Inc.'s seasonal vaccine business and helping to stabilize revenue streams in the short term.

Moderna
Bear Case

Investors should be bearish about investing in Moderna, Inc. for these reasons:

Moderna, Inc. remains unprofitable with a negative price-to-earnings ratio of -17.99 and a negative net margin of 141.43%, meaning the company is still losing money on every dollar of revenue and has not yet achieved financial sustainability.
CFO Jamey Mock sold 34,836 shares of Moderna, Inc. stock for approximately $4.7 million, reducing his direct ownership by nearly 37%, which may weigh on investor sentiment despite the transaction being executed under a pre-arranged trading plan.
Analyst opinions remain divided with a consensus rating of "Hold" and an average price target of $76.72, which is significantly below the current stock price of $143.77, suggesting that many sell-side analysts believe the stock is overvalued relative to its fundamental earnings potential.
The company faces intense competition in the cancer vaccine space, with at least five other drugmakers actively pursuing similar opportunities, which could limit Moderna, Inc.'s market share and pricing power in this emerging therapeutic area.
Short interest in Moderna, Inc. remains elevated with approximately 39.15 million shares shorted, representing about 11% of the float, indicating that a significant portion of the market is betting against the stock's future performance.

MRNA Forecast - Frequently Asked Questions

According to the research reports of 24 Wall Street equities research analysts, the average twelve-month stock price forecast for Moderna is $76.72, with a high forecast of $180.00 and a low forecast of $18.00.

24 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Moderna in the last year. There are currently 5 sell ratings, 12 hold ratings and 7 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" MRNA shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in MRNA, but not buy additional shares or sell existing shares.

According to analysts, Moderna's stock has a predicted downside of -50.19% based on their 12-month stock forecasts.

Over the previous 90 days, Moderna's stock had 6 upgrades and 2 downgrades by analysts.

Moderna has been rated by research analysts at Argus, Bank of America, Barclays, Bradesco Corretora, Brookline Capital Markets, Citigroup, CLSA, Deutsche Bank Aktiengesellschaft, Jefferies Financial Group, JPMorgan Chase & Co., Loop Capital, Morgan Stanley, Piper Sandler, Rothschild & Co Redburn, Royal Bank Of Canada, The Goldman Sachs Group, UBS Group, Weiss Ratings, William Blair, and Wolfe Research in the past 90 days.

Analysts like Moderna less than other "healthcare" companies. The consensus rating score for Moderna is 2.08 while the average consensus rating score for "healthcare" companies is 2.30. Learn more on how MRNA compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Analyst Ratings

Top-Rated Stocks

More Ratings Tools

Brokerages With Moderna Recommendations

MarketBeat monitors more than a dozen sources for Moderna analyst ratings, with the most recent rating issued on 9/9/2026.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Moderna (MRNA) Stock Forecast & Price Target